Literature DB >> 10052728

Recurrent fetal polycystic kidneys associated with glutaric aciduria type II.

S Kjaergaard1, N Graem, T Larsen, F Skovby.   

Abstract

A woman had two pregnancies terminated in the 20th and 21st weeks of gestation after ultrasonographic detection of enlarged hyperechoic kidneys in both fetuses. The combination of polycystic kidneys and steatotic liver found at autopsy suggested glutaric aciduria type II (GA II), which was confirmed by biochemical investigation. GA II or multiple acyl-CoA dehydrogenase deficiency is an autosomal recessively inherited defect of mitochondrial energy metabolism, which usually results in neonatal death. When pregnancy is terminated because of enlarged hyperechoic kidneys in the fetus, autopsy is crucial for establishing the correct diagnosis. The combination of polycystic kidneys and steatotic liver should bring GA II to mind, and prompt appropriate biochemical investigations so that genetic counselling and first trimester diagnosis can be offered in future pregnancies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10052728     DOI: 10.1111/j.1699-0463.1998.tb00276.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  7 in total

1.  Disorders of fatty acid oxidation and autosomal recessive polycystic kidney disease-different clinical entities and comparable perinatal renal abnormalities.

Authors:  Agnes Hackl; Katrin Mehler; Ingo Gottschalk; Anne Vierzig; Marcus Eydam; Jan Hauke; Bodo B Beck; Max C Liebau; Regina Ensenauer; Lutz T Weber; Sandra Habbig
Journal:  Pediatr Nephrol       Date:  2017-01-12       Impact factor: 3.714

Review 2.  Inborn errors of metabolism for the diagnostic radiologist.

Authors:  Chris J Hendriksz
Journal:  Pediatr Radiol       Date:  2008-12-13

Review 3.  Therapeutic microRNAs in polycystic kidney disease.

Authors:  Matanel Yheskel; Vishal Patel
Journal:  Curr Opin Nephrol Hypertens       Date:  2017-07       Impact factor: 2.894

4.  Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Lauren Pickel; Ioan-Andrei Iliuta; James Scholey; York Pei; Hoon-Ki Sung
Journal:  Adv Nutr       Date:  2021-11-10       Impact factor: 8.701

5.  PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice.

Authors:  Ronak Lakhia; Matanel Yheskel; Andrea Flaten; Ezekiel B Quittner-Strom; William L Holland; Vishal Patel
Journal:  Am J Physiol Renal Physiol       Date:  2017-09-13

6.  A novel ETFB mutation in a patient with glutaric aciduria type II.

Authors:  Yosuke Sudo; Ayako Sasaki; Takashi Wakabayashi; Chikahiko Numakura; Kiyoshi Hayasaka
Journal:  Hum Genome Var       Date:  2015-06-18

7.  microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism.

Authors:  Sachin Hajarnis; Ronak Lakhia; Matanel Yheskel; Darren Williams; Mehran Sorourian; Xueqing Liu; Karam Aboudehen; Shanrong Zhang; Kara Kersjes; Ryan Galasso; Jian Li; Vivek Kaimal; Steven Lockton; Scott Davis; Andrea Flaten; Joshua A Johnson; William L Holland; Christine M Kusminski; Philipp E Scherer; Peter C Harris; Marie Trudel; Darren P Wallace; Peter Igarashi; Edmund C Lee; John R Androsavich; Vishal Patel
Journal:  Nat Commun       Date:  2017-02-16       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.